Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Erlotinib Versus Combination of Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage IIIA Non-small-cell Lung Cancer After Complete Resection With Sensitizing EGFR Mutation in Exon 19 or 21 and Wild-type K-ras

NCT01410214 is registered in ClinicalTrials.gov with Chinese Lung Cancer Surgical Group as lead sponsor.

NCT NCT01410214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01410214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Erlotinib Versus Combination of Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage IIIA Non-small-cell Lung Cancer After Complete Resection With Sensitizing EGFR Mutation in Exon 19 or 21 and Wild-type K-ras
Lead sponsor
Chinese Lung Cancer Surgical Group
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2011
Completion date
July 31, 2017
Enrollment
80 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer stage iiia